HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Frye, C. A. Search for Related Content PubMed PubMed Citation Articles by Frye, C. A.

Neurology supplements are not peer-reviewed. Information contained in Neurology supplements represent the opinions of the authors and are not endorsed by nor do they reflect the views of the American Academy of Neurology, Editor-in-Chief, or Associate Editors of Neurology.

An overview of oral contraceptives

Mechanism of action and clinical use

From the Center for Neuroscience Research, University at Albany, State University of New York, Albany, New York.

Address correspondence to Dr. Cheryl A. Frye, Departments of Psychology, Biology, and Center for Neuroscience Research, University at Albany, State University of New York, 1400 Washington Avenue, Albany, NY 12203. Phone: (518) 442-4836 Fax: (518) 442-4867

Hormonal contraception is available in oral contraceptive pills and in newer formulations, including the transdermal patch, the vaginal ring, subcutaneous implants, and IM injections. Prevention of pregnancy is achieved by inhibiting ovulation, fertilization, and/or implantation of an egg. Hormonal contraception provides effective, tolerable, and reversible prevention of pregnancy. Efficacy and safety profiles are similar for different formulations and administration routes. Lowest expected failure (i.e., method failure) rates for hormonal contraceptives, regardless of formulation, are <2%. Typical failure rates for oral formulations range from <3% to 5% due to failures in compliance. The most commonly reported adverse effects are weight gain, nausea, variations in menstrual flow, breast changes such as tenderness, discomfort, or swelling, depression or mood disturbances, decreased sexual desire or response, and acne. Rare but serious potential effects include cardiovascular diseases, such as stroke, and an increased risk for breast cancer, liver tumors, and gallbladder disease. Hormonal contraceptive use should be avoided in women at risk for blood clots, by heavy smokers, and in women with breast or other cancers. Use of hormonal contraception in adolescents requires special consideration, in part because of decreased compliance.

Publication of this supplement was supported by an educational grant from UCB Pharma Inc. The sponsor has provided the author with an honorarium for her participation in this project.

This article has been cited by other articles:

				G.C. Lasiuk and K.M. Hegadoren The Effects of Estradiol on Central Serotonergic Systems and Its Relationship to Mood in Women Biol Res Nurs, October 1, 2007; 9(2): 147 - 160. [Abstract] [PDF]